Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AEV 103

Drug Profile

AEV 103

Alternative Names: 3,6’-dithiopomalidomide; 3,6’-DP; AEV-103

Latest Information Update: 13 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer AevisBio; National Institute on Aging; National Institutes of Health (USA); Yonsei University
  • Class Imides; Small molecules
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Brain injuries

Most Recent Events

  • 12 Apr 2022 AEV 103 is under IND-enabling studies in South Korea (AevisBio pipeline, April 2022)
  • 08 Mar 2022 Preclinical trials in Brain injuries in South Korea (unspecified route) (AevisBio pipeline, March 2022)
  • 08 Mar 2022 Pharmacodynamics data from a preclinical study in Alzheimer's disease released in AevisBio
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top